Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2017 2
2018 1
2019 2
2020 1
Text availability
Article attribute
Article type
Publication date

Search Results

6 results
Results by year
Filters applied: . Clear all
Page 1
Pharmacology of cannabinoids in the treatment of epilepsy.
Gaston TE, Friedman D. Gaston TE, et al. Epilepsy Behav. 2017 May;70(Pt B):313-318. doi: 10.1016/j.yebeh.2016.11.016. Epub 2017 Jan 10. Epilepsy Behav. 2017. PMID: 28087250 Review.
This article summarizes the available scientific data of pharmacology from human and animal studies on the major cannabinoids which have been of interest in the treatment of epilepsy, including ∆9-tetrahydrocannabinol (∆9-THC), cannabidiol (CBD), ∆9-tetrahydrocannabivarin …
This article summarizes the available scientific data of pharmacology from human and animal studies on the major cannabinoids which have bee …
Cannabis Therapeutics and the Future of Neurology.
Russo EB. Russo EB. Front Integr Neurosci. 2018 Oct 18;12:51. doi: 10.3389/fnint.2018.00051. eCollection 2018. Front Integr Neurosci. 2018. PMID: 30405366 Free PMC article.
This review will examine the intriguing promise that recent discoveries regarding cannabis-based medicines offer to neurological therapeutics by incorporating the neutral phytocannabinoids tetrahydrocannabinol (THC), cannabidiol (CBD), their acidic precursors, tetrahydrocannabino …
This review will examine the intriguing promise that recent discoveries regarding cannabis-based medicines offer to neurological therapeutic …
The current status of artisanal cannabis for the treatment of epilepsy in the United States.
Sulak D, Saneto R, Goldstein B. Sulak D, et al. Epilepsy Behav. 2017 May;70(Pt B):328-333. doi: 10.1016/j.yebeh.2016.12.032. Epub 2017 Feb 21. Epilepsy Behav. 2017. PMID: 28254350 Clinical Trial.
The widespread patient use of artisanal cannabis preparations has preceded quality validation of cannabis use for epilepsy. Neurologists and cannabinoid specialists are increasingly in a position to monitor and guide the use of herbal cannabis in epilepsy patients. …
The widespread patient use of artisanal cannabis preparations has preceded quality validation of cannabis use for epilepsy. Neurologi …
Simultaneous Quantification of 13 Cannabinoids and Metabolites in Human Plasma by Liquid Chromatography Tandem Mass Spectrometry in Adult Epilepsy Patients.
Roslawski MJ, Remmel RP, Karanam A, Leppik IE, Marino SE, Birnbaum AK. Roslawski MJ, et al. Ther Drug Monit. 2019 Jun;41(3):357-370. doi: 10.1097/FTD.0000000000000583. Ther Drug Monit. 2019. PMID: 30520828
METHODS: A liquid chromatography tandem mass spectrometry method was developed and validated to measure 13 cannabinoid compounds: cannabidiol (CBD), cannabidiolic acid, cannabidivarin, cannabinol, cannabigerol, cannabigerolic acid, cannabichromene, Δ-tetrahydocannabinol (THC), Δ- …
METHODS: A liquid chromatography tandem mass spectrometry method was developed and validated to measure 13 cannabinoid compounds: cannabidio …
Development of a validated method for the qualitative and quantitative analysis of cannabinoids in plant biomass and medicinal cannabis resin extracts obtained by super-critical fluid extraction.
Elkins AC, Deseo MA, Rochfort S, Ezernieks V, Spangenberg G. Elkins AC, et al. J Chromatogr B Analyt Technol Biomed Life Sci. 2019 Mar 1;1109:76-83. doi: 10.1016/j.jchromb.2019.01.027. Epub 2019 Jan 30. J Chromatogr B Analyt Technol Biomed Life Sci. 2019. PMID: 30738340
Cannabis is being used for treatment for conditions such as epilepsy, cancer and pain management. There are a range of medicinal cannabis products available, but the use of cannabis resin obtained by super critical fluid extraction, often diluted in oil, is becoming increa …
Cannabis is being used for treatment for conditions such as epilepsy, cancer and pain management. There are a range of medicinal cann …
A Systematic Review of Minor Phytocannabinoids with Promising Neuroprotective Potential.
Stone NL, Murphy AJ, England TJ, O'Sullivan SE. Stone NL, et al. Br J Pharmacol. 2020 Jul 1. doi: 10.1111/bph.15185. Online ahead of print. Br J Pharmacol. 2020. PMID: 32608035 Review.
CBG (range 5 mg.kg(-1) to 20 mg.kg(-1) ) and CBDV (range 0.2 mg.kg(-1) to 400 mg.kg(-1) ) displayed efficacy in models of Huntington's disease and epilepsy. CBC (10-75 mg.kg(-1) ), Δ(9) -THCA (20 mg.kg(-1) ) and Δ(9) -THCV (range 0.025-2.5 mg.kg(-1) ) showed …
CBG (range 5 mg.kg(-1) to 20 mg.kg(-1) ) and CBDV (range 0.2 mg.kg(-1) to 400 mg.kg(-1) ) displayed efficacy in models of Huntington's
Feedback